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Abstract
Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the United-States. The aim of the
study was to describe serum immune profiles associated with acute DILI, to investigate whether there are profiles
associated with clinical features or types of DILI and/or with prognosis, and to assess temporal changes in levels.
Twenty-seven immune analytes were measured in the sera of 78 DILI subjects in the Drug-Induced Liver Injury
Network (DILIN) and compared with 40 healthy controls. Immune analytes (14 cytokines, 7 chemokines and 6 growth
factors) were measured by BioPlex multiplex ELISA at DILI onset and after 6 months. A modeling process utilizing
immune principles was used to select a final set of variables among 27 immune analytes and several additional
clinical lab values for prediction of early death (within 6 months of DILI onset). Nineteen of the 27 immune analytes
were differentially expressed among healthy control, DILI onset and 6-month cohorts. Disparate patterns of immune
responses, especially innate and adaptive cellular (mostly TH17) immunity were evident. Low values of four immune
analytes (IL-9, IL-17, PDGF-bb and RANTES) and serum albumin are predictive of early death [PPV = 88% (95% CI,
65%-100%), NPV = 97% (95% CI, 93%-100%), accuracy = 96% (95% CI, 92%-100%)].
Conclusions: Acute DILI is associated with robust and varying immune responses. High levels of expression of
cytokines associated with innate immunity are associated with a poor prognosis, whereas high levels of expression of
adaptive cytokines are associated with good long-term prognosis and eventual recovery. Serum immune analyte
profiles at DILI onset appear to be of prognostic, and perhaps, diagnostic significance.
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Introduction
Liver injury caused by drugs and chemicals is a problem that
continues to grow in prevalence and importance. Drug induced
liver injury (DILI) is a common cause of acute liver failure in the
United States [1-3]. DILI is also a frequent adverse drug event
that leads to the abandonment of otherwise promising new
drug candidates or to the withdrawal from the market of new
drugs [4,5].
There are many challenges to making a clear diagnosis of
DILI, because there is no pathognomonic test or “gold
standard” for establishing the diagnosis. Rather, it is usually a
diagnosis of exclusion, after compatible history of drug
exposure has been elicited and other more frequent or likely
causes have been excluded [6,7]. The problem is compounded
by the growing use of herbal remedies and dietary
supplements (HDS), which account for ~10% of instances of
DILI in the USA [8] and even higher frequencies in the Far East
[9]. Furthermore, there are difficulties in predicting the
prognosis of acute DILI. Levels of the most commonly used
biomarkers, (e.g. serum aminotransferases, alkaline
phosphatase, or other enzymes) are of limited sensitivity and
specificity [7,10]. Addition of serum total bilirubin, especially in
hepatitis-type injury with increases chiefly in serum
aminotransferases, is useful, as was emphasized by
Zimmerman more than 30 years ago. Clinically apparent
jaundice with elevated levels of serum total bilirubin and high
levels of serum aminotransferases due to drugs are ominous,
with about 10% of subjects succumbing during the acute phase
of illness [11]. Better biomarkers and early warning signals of
serious, potentially fatal DILI are urgently needed [5,10].
Changes in levels of circulating cytokines and chemokines
have been proposed as possible biomarkers of tissue injury,
including liver injury due to drugs [5]. Indeed, several cytokines
[12-16], and individual or small groups of cytokines have been
reported to be altered in a few experimental studies of DILI
[17-21]. For example, in one study in humans, genetic
polymorphisms associated with lower production of IL-10, were
associated with lower eosinophil counts and poorer outcomes
[13].
The aim of this study was to describe serum immune profiles
associated with acute DILI, to investigate whether there are
profiles associated with clinical features or types of DILI and/or
with prognosis, and to assess temporal changes in levels of the
analytes. To achieve these aims, we simultaneously measured
levels of 27 immune analytes in the sera of subjects with well-
characterized, carefully studied, acute DILI, who were then
followed for at least one year in the prospective US Drug-
Induced Liver Injury Network. This Network and its major
methods have been described previously [8,22,23], and
findings in the first three hundred subjects enrolled have been
described [8]. In this work, we compared results from 78
subjects with acute DILI, with those of 40 normal controls in
whom serum proteomic profiles were reported recently [24].
We observed striking changes in innate and adaptive cellular
responses, and we also developed a new means for early
prediction of outcomes, based upon results at initial acute
presentation for four serum immune analytes (interleukin[IL] 9,
IL 17, platelet derived growth factor bb, and RANTES) and the
level of the serum albumin. Some of these results have been
presented in abstract form [25].
Materials and Methods
Subjects studied
Serum samples from subjects with DILI were collected as
part of the Drug Induced Liver Injury Network (DILIN)
prospective study, in which subjects with suspected DILI were
enrolled and detailed clinical data were collected [22]. Written
informed consent was obtained at that time. Clinical data were
reviewed by the DILIN Causality Committee, which made the
final determination as to whether the case qualified as bona
fide DILI, and assigned each implicated drug a probability of
having caused DILI [23]. Types of liver injury and R-values
were as described [8,24]. We studied 78 subjects with acute
DILI, enrolled between December 2004 and July 2010, and
who had serum samples taken within two weeks of clinical
onset. These were the same subjects whose serum proteomic
profiles were described by Bell et al [24]. The study protocol
was approved by the Institutional Review Board of Indiana
University-Purdue University, Indianapolis, Indiana (Dr. Naga
Chalasani as PI). Whenever possible, subjects were followed
for at least 6 months to assess whether there was recovery or
evidence of development of chronic DILI. Blood samples were
collected and sent to the central DILIN sample repository for
processing and storage at -80°C. Sera from 40 healthy controls
(volunteer blood donors) were obtained from a blood bank [24].
These controls had no history or evidence of liver disease, had
normal serum levels of ALT, AST, AP, and total serum bilirubin,
and had no serological evidence of active HAV, HBV, HCV, or
HIV infection.
Immune analyte profiling by Bio-Plex assay
Concentrations of immune analytes in sera were determined
using a human 27-plex assay [14 cytokines (IL-1β, IL-1ra, IL-2,
IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, IFN-γ,
TNF-α); 7 chemokines (Eotaxin, IL-8, IP-10, MCP-1, MIP-1α,
MIP-1β, RANTES); and 6 growth factors (IL-7, FGF basic, G-
CSF, GM-CSF, PDGF-BB, VEGF)] (Bio-Plex Suspension Array
System, Bio-Rad, Hercules, CA, USA), following the
manufacturer’s instructions. Samples were diluted 1:4 (v:v) in
sample diluent and incubated for 30 minutes (room
temperature, 300 rpm agitation) with capture antibody-coupled
magnetic beads. Following three washes in a Bio-Plex Pro
wash station, samples were incubated for 30 minutes in the
dark (room temperature, 300 rpm agitation) with biotinylated
detection antibody. Each captured analyte was detected by the
addition of streptavidin-phycoerythrin and quantified using a
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BioPlex array reader. Analyte concentrations were calculated
with Bio-Plex Manager software.
Heat-maps of immune analytes in DILI subjects
To generate cytokine heat-maps that were used to establish
and compare immune response patterns among DILI subjects,
we grouped cytokines, based on the major known transcription
factors that trigger their expression and the immune processes
to which they primarily relate, as follows: cytokines associated
with innate immunity (NFκB-dependent): IL-1β, IL-6, TNFα;
cytokines associated with adaptive cellular immunity (T-box
transcription factor TBX21/T-bet or RoRγt-dependent):
IL-12p70, IFNγ, IL-2, IL-15, IL-17; cytokines associated with
adaptive humoral immunity (Gata3 or IRF-4-dependent): IL-4,
IL-5, IL-13, IL-9; and cytokines associated with immuno-
suppression / resolution of inflammation: IL-1ra, IL-10 [26-30]
(Figure 1).
Normal ranges for serum concentrations of immune analytes
were based on measurements obtained from the healthy
controls and recorded as mean ± 1 standard deviation (SD).
Concentrations in sera of DILI subjects 1 SD higher or lower
than the means of healthy subjects were defined as abnormal.
We identified four main immune profiles, based on patterns of
abnormal cytokine expression among the DILI cohort at onset:
1) DILI of “mixed-immune” profile in which at least 1 innate and
1 or more adaptive cellular and humoral cytokine
concentrations were higher than normal; 2) DILI of “innate
immune” profile in which 1 or more innate cytokine
Figure 1.  Simplified model of immune responses.  Immune
stimuli trigger NFκB nuclear translocation and early/innate
cytokine production (IL-1β, IL-6, TNF-α) by damaged tissue. If
this early inflammatory state persists, it will activate adaptive
immune processes favoring either cellular (T-box transcription
factor TBX21 (e.g., T-bet)-dependent / TH1-type: IL-12p70,
IFNγ, IL-2, IL-15) or humoral (Gata3-dependent /TH2-type:
IL-4, IL-5, IL-13) responses. This inflammatory state may
ultimately resolve itself by triggering anti-inflammatory
processes (IL-10, IL-1ra). In the event of an unresolved
inflammatory state, innate and anti-inflammatory processes
synergize to evolve into RoRγt-dependent / TH17-type: IL-17 or
IRF4-dependent TH9-type IL-9 adaptive immunity.
doi: 10.1371/journal.pone.0081974.g001
concentrations were higher than normal and no adaptive
cytokine was higher than normal; 3) DILI of “adaptive immune”
profile in which 1 or more adaptive cellular or humoral cytokine
concentrations were higher than normal; and 4) DILI of
“normal-immune” profile with no abnormal innate cytokine and
at most one abnormal adaptive cytokine concentrations. DILI
immune profiles that did not match any of the criteria described
above were labeled as “uncategorized.”
Statistical Methods
Descriptive statistics, including means and standard
deviations, or counts and percentages were calculated. For
data measured on the interval scale, the Student’s t-test or
analysis of variance (ANOVA) was used. If the data were not
normally distributed, the Wilcoxon rank sum test or the Kruskal-
Wallis test was employed. The paired t-test or Wilcoxon signed
rank test was used for comparing baseline values and the
values at six months. For nominal data, the chi-square or
Fisher’s exact test was employed. Spearman’s correlations
were used to test for linear relationships between the variables
measured on the interval scale. Unless specified otherwise, a
two-tailed p-value of less than 0.05 was considered statistically
significant. SAS® version 9.2 was used for all analyses.
The following modeling process was used to select variables
among 27 immune analytes and 2 clinical lab test results
(serum albumin or total bilirubin) for prediction of early death
(within 6 month of DILI onset). Due to small sample size and
the relatively large number of variables, the goal was to find a
stable model (34) with small numbers of variables that are
highly predictive of early death. In the first step, univariate
analyses were carried out to compare those died within 6
months of DILI onset vs. those who survived by using the
Wilcoxon rank sum test. To be highly selective, only those
variables that were statistically significant at p < 0.01 level were
considered in the second step. It was expected that the
immune analytes within each of the following three groups are
likely to be correlated: cytokines, chemokines and growth
factors. Thus in the second step, we examined the pairwise
correlations within each group. We started out with the immune
analyte that had the highest association with early death
(lowest p-value). Only immune analytes within the group that
were not significantly correlated with this immune analyte were
retained for further consideration. If the pairwise correlations of
the remaining immune analytes were significant, then we
excluded the immune analyte with the lower association with
early death from the pair. In the third step, we excluded
immune analytes within the group that were poorly modulated
based on heat-maps profiles of expressions. As a final step, we
obtained the final set of the variables by examining the pairwise
correlations among the remaining immune analytes and the
clinical lab values. If the pairwise correlations were significant,
then we excluded the variable with the lower association with
early death from the pair.
Once the final set of variables had been selected, the area
under curve (AUC) was estimated for each variable to evaluate
its potential prognostic and diagnostic value. Logistic
regression model with all of these variables was fit to estimate
the AUC based on the fitted model with linear combination of
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the variables as a predictor. The linear combination of these
variables may not be the best predictor for early death because
the values of the immune analytes can tend to be skewed.
Thus, the following binary variables were created as predictors.
The immune analytes were dichotomized at observed median
values and the clinical lab values were dichotomized based on
established clinical cut points. Two summary binary variables
were created, one based on binary immune analytes only and
the other based on both the binary immune analytes and the
clinical lab data. We expect that the binary variable based on
both immune analytes and clinical lab data to have the highest
predictability for early death. This binary variable has a value of
1 if values of the variables (immune analytes and clinical lab
values) all fall in the binary category that was predictive of early
death based on direction of association, and a value of 0
otherwise. The predictability of this binary variable for early
death was evaluated by positive predictive value (PPV),
negative predictive value (NPV) and accuracy (percent of
correct prediction). Sensitivity and specificity were also
calculated.
Results
Characteristics of Study Cohorts
Seventy-eight subjects with acute DILI and 40 healthy
controls were included in the study [24] (Figure 2). Thirty-seven
subjects with DILI completed 6-month follow-up visits among
whom, sera were obtained in 32 subjects. [Due to various
reasons, 5 subjects did not provide serum samples at 6
months]. Ten subjects (12.8%) died within 6 months of DILI
onset, whereas one died of a non-DILI cause after 315 days.
None underwent liver transplantation.
Demographic and lab data are presented in Table 1. The
mean age of the DILI cohort was 48 (±17.9) years old. Gender
Figure 2.  Flow diagram of study cohort.  Sera from 78 DILI
subjects and 40 healthy controls (volunteer blood donors) were
analyzed in the study. Among those patients with acute DILI,
10 died within 6 months of DILI onset and 37 returned for a 6-
month follow-up visit, among whom serum samples were
obtained from 32.
doi: 10.1371/journal.pone.0081974.g002
distribution was 55% women, and 73% were Caucasian
[European-American]. As shown in Table 2, 59%, 22%, 15%
and 4% of DILI subjects, respectively, presented with
hepatocellular, cholestatic, mixed or unknown patterns of liver
injury, similar to those of the entire DILI cohort [8].
Table 1. Selected demographic, clinical, and laboratory









Age, mean ± SD (y) 48 ± 17.9 51 ± 14.2 49.2 ± 13.1
Female (%) 55 55 28
Self-reported race (%)    
White 73 73 95
Black 10 10 5
Other 16 15 0
Unknown 1 0 0
Body mass index, mean ± SD
(kg/m2)
27.1 ± 6.5  30.5 ± 6.9
Absolute eosinophils/µL
(mean ± SD)
173± 235   
Liver biochemistries, mean ±
SD
   
ALT (U/L) 1065 ± 1382 55±131 17± 5
AST (U/L) 1003 ± 1249 38±47 24 ± 5
Alkaline phosphatase (U/L) 336± 465 89±33 63± 14
Total bilirubin (mg/dL) 8.1 ± 7.4 0.9±0.7 0.6 ± 0.2
INR 1.8 ± 1.2 1.1±0.4  
Abbreviations: DILI, Drug-induced liver injury; SD, standard deviation; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; INR, international normalized
ratio.
doi: 10.1371/journal.pone.0081974.t001
Table 2. Selected DILI characteristics and outcomes
among subjects studied [n= 78].










Liver-related mortality (%) 6
Chronic DILI (%) 5
doi: 10.1371/journal.pone.0081974.t002
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Longitudinal analysis: immune analytes and the course
of DILI
Experimental models of DILI and retrospective clinical
studies [12-15,17-21] have posited immune activation
mechanisms associated with acute liver injury. In order to
characterize immune components associated with DILI
regardless of the pattern and severity of injuries, serum levels
of immune analytes were compared among DILI onset (n=78),
6-month follow-up (n=32) and healthy controls (n=40). The
three groups displayed a high degree of heterogeneity. For 26
of the 27 immune analytes, the results were not normally
distributed.
A Wilcoxon rank-sum test was performed to assess which
cytokines, chemokines or growth factors, were altered in DILI
(Figure 3, 4 and Table S1 in File S1). Distributions of serum
levels of 6 immune analytes significantly differed among
healthy controls (n=40), DILI at onset (n=78) and DILI at 6-
month follow up (n=32): IL-4, IL-9, eotaxin, RANTES, PDGF-
bb, and MCP-1 (Figure 3). In addition, serum levels of 8
immune analytes were differently distributed between control
and DILI at onset (IL-5, IL-6, IL-7, IL-8,IL-13, IP-10, FGF basic,
IFN-γ,), and 4 (IL-2, IL-15, VEGF, MIP-1β) were differently
distributed between control and DILI at 6-month follow-up
(Figure 4). For those subjects with 6-month follow-up samples
(n=32), the differences between the baseline and follow-up
samples were examined. Significant changes were observed
for 8 immune analytes (IL-5, IL-8, IP-10, IFNγ, FGF basic,
MIP-1β, GM-CSF and VEGF) (Table S2 in File S1). Overall,
among the 27 immune analytes investigated, 19 showed
significant differences among healthy controls and DILI at
onset and/or at 6-month follow-up.
Among those who survived for more than 6 months, all
showed marked clinical and biochemical improvement in DILI.
Comparative analysis of immune analyte pattern(s) of
DILI subjects
To provide a framework better to understand the
heterogeneity observed in control, DILI onset, and DILI 6-
month groups, immune profiles of individual DILI subjects were
assessed and compared. These immune profiles, were
established based on observed patterns of cytokine serum
levels and from consideration of known immunological
principles. While the function and origin of individual immune
analytes can be determined, cytokines actually function in
networks (synergy, antagonism). For instance, in a simplified
model of immune processes (Figure 1), an immune stimulus
(e.g., cell damage caused by a drug or other chemical) triggers
NFκB nuclear translocation and early/innate cytokine
production (IL-1β, IL-6, TNF-α) by damaged tissue. If this early
Figure 3.  Immune analytes concentrations differentially distributed among control, DILI onset and 6-month follow up
samples.  Box-and whisker plot: Turkey representation (i.e. 25-75 percentile +/- 1.5 interquartile distance) of immune analytes
concentration in sera collected from control, DILI onset and 6-month follow up. Immune analytes measurements are in pg/mL. *
Comparisons of all distributions to control samples are statistically significant (p<0.05) by Wilcoxon rank sum test. § Comparisons of
the difference between DILI onset and 6-month follow up distributions are statistically significant (p<0.05) by paired t-test or
Wilcoxon rank sum test.
doi: 10.1371/journal.pone.0081974.g003
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Figure 4.  Immune analytes concentrations differentially distributed between control, DILI onset or 6-month follow up
samples.  Box-and whisker plot: Turkey representation (i.e. 25-75 percentile +/- 1.5 interquartile distance) of immune analytes
concentration in sera collected from control, DILI onset and 6-month follow up. Immune analytes measurements are in pg/mL. *
Comparisons of DILI onset or 6-month follow up distribution to control samples are statistically significant (p<0.05) by Wilcoxon rank
sum test. § Comparisons of the difference between DILI onset and 6-month follow up distributions are statistically significant
(p<0.05) by paired t-test or Wilcoxon rank sum test.
doi: 10.1371/journal.pone.0081974.g004
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inflammatory state persists, it will activate adaptive immune
processes favoring either cellular (T-bet-dependent / TH1-type:
IL-12p70, IFNγ, IL-2, IL-15; RoRγt-dependent / TH17-type:
IL-17), or humoral (Gata3-dependent / TH2-type: IL-4, IL-5,
IL-13; IRF4-dependent / TH9-type: IL-9) responses [26,27,30].
If the inciting agent (in this case a causative drug) is removed,
usually, immune responses will ultimately resolve themselves
by triggering anti-inflammatory processes (IL-10, IL-1ra) [29].
Four distinct immune profiles emerged among DILI subjects
at the onset of the disease (n=78) (Figure 5, Figure S1).
Nineteen subjects displayed an “innate immune” profile with
one or more early/innate cytokines higher than normal. Twenty-
one DILI subjects showed an “adaptive immune” profile with at
least one adaptive cytokine higher than normal. Four DILI
subjects had a “mixed-immune” profile (both early and innate
cytokines higher than normal), and 8 a “normal-immune” profile
(no abnormal innate and 1 or fewer abnormal adaptive cytokine
levels). Twenty-six DILI subjects were uncategorized (2 or
more abnormal cytokines levels). Of note, among the 21 DILI
subjects with an “adaptive immune” cytokine profile, classical
TH1 and TH2 adaptive responses were rare. Rather at DILI
onset, TH17 (15.4%) and TH9 (6.4%) increases predominated
(Figure 5, Figure S1).
Using a similar methodology to compare the 32 DILI subjects
for whom 6-month follow-up samples and data were available,
at 6 months 12 exhibited normal or lower than normal serum
cytokine levels and 17 DILI subjects showed higher than
normal serum levels of adaptive cytokines (Figure 6, Figure
S2). Among the cohort of 32, over-expressed adaptive
cytokines were predominantly TH1 (6/32) or cellular/humoral
hybrid (6/32). Only a few displayed TH17 (4/32) or TH9 profiles
(1/32) (Figure 7, Figure S3).
Immune Analytes and Clinical Features of DILI
Correlations among clinical features and cytokine levels were
explored. Several cytokines, chemokines and growth factors
were found to be significantly associated with
hyperbilirubinemia (serum total bilirubin >1.2mg/dL) and self-
reported jaundice (Table 3). Those with hyperbilirubinemia or
self-reported jaundice had mean serum ALT and AST levels
that were not significantly different from those of other DILI
subjects. The median values for nearly all of the immune
analytes were higher for subjects with hyperbilirubinemia or
self-reported jaundice compared to those without. No
significant association was evident for the following clinical
features and any of the cytokines measured: gender, age,
pattern of DILI, severity of DILI, serum ALT at onset, peak
serum ALT, serum AP at onset, peak serum AP, R value, BMI,
absolute eosinophil count. There were also no significant
associations among concentrations of immune analytes and
individual drugs implicated in causing DILI (Table 4). Grouping
causative drugs into major therapeutic classes [e.g., anti-
infectious agents, anti-convulsants, anti-hypertensive agents,
lipid lowering agents, etc] did not uncover significant
correlations among classes of drugs or their indications for use
and immune profiles. Rather, causative agents were to be
found in several different types of immune response.
Figure 5.  Profiles of immune analytes in serum at onset of
DILI.  Individual cytokine concentrations in sera obtained close
to (within 14 days of) DILI onset were recorded for each patient
and compared with healthy “normal” means ± SD values.
Abnormal serum cytokine concentrations at DILI onset were
defined as values that were higher (red) or lower (blue) than
those of the means for normal controls. The profiles of DILI
subjects at onset were defined based on observed similarities
of patterns and upon knowledge of the physiologic roles of the
analytes (see text and Fig 1).
doi: 10.1371/journal.pone.0081974.g005
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Among the 10 subjects who died within 6 months following
DILI onset, 5 displayed an “innate DILI” cytokine profile while
only 1 had a TH17 signature (Figure 7, Figure S3). The
remaining 4 subjects had an “uncategorized” cytokine profile,
and deaths tended to occur later in these subjects compared
with those with “innate DILI” profile (median time of death
following DILI onset 72 days vs. 6 days).
Figure 6.  Profiles of cytokines in sera of DILI subjects at 6-
month follow-up.  Individual cytokine concentrations in 6-
month follow-up sera were recorded for each patient and
compared with healthy “normal” means ± SD values. Abnormal
serum cytokine concentrations at 6-mo follow-up were defined
as measurements SD higher (red) or lower (blue) than those of
the means for normal controls. The profiles of DILI subjects at
6 month follow up were defined based on observed similarities
of patterns and upon knowledge of the physiologic roles of the
analytes (see text and Fig 1).
doi: 10.1371/journal.pone.0081974.g006
Figure 7.  Cytokine profiles in sera of subjects who died
within 6 months of DILI onset.  Individual cytokine
concentrations were recorded for each patient and compared
with healthy “normal” means ± SD values. Abnormal serum
cytokine concentrations were defined as measurements SD
higher (red) or lower (blue) than those of the means for normal
controls. The profiles of DILI subjects who died within 6 months
of DILI onset were based on observed similarities of patterns
and upon knowledge of the physiologic roles of the analytes
(see text and Fig 1).
doi: 10.1371/journal.pone.0081974.g007
Table 3. Serum levels at DILI onset of immune analytes
significantly associated with an elevation of serum total
bilirubin.
 
Serum Total Bilirubin >1.2
mg/dL (n = 59)
Serum Total Bilirubin 0 - 1.2
mg/dL (n = 17)
p
value*
 Median Min. Max. Median Min. Max.  
IL-1β 1.0 0.0 48.2 0.6 0.0 2.5 0.035
IL-1ra 145.6 29.1 719.6 81.6 4.7 1406 0.007
IL-5 3.1 0.5 68.4 2.1 0.0 6.5 0.0156
IL-7 8.0 1.4 165.0 3.7 0.0 13.8 0.0131
IL-8 82.7 15.6 4636 42.7 7.4 463.1 0.0043
IP-10 2163.6 222.6 48050 835.2 71.9 39266 0.0124
MIP-1α 3.6 0.0 80.1 1.4 0.0 12.0 0.0184
MIP-1β 99.5 19.3 473.8 54.7 15.6 158.4 0.0011
PDGF-
bb
4819 65.3 28757 1772.5 130.9 15951 0.0101
All results are pg/mL. Values listed as zero are out of assay operating range.
* Comparisons of distributions are statistically significant (p<0.05) by Wilcoxon
rank-sum test.
doi: 10.1371/journal.pone.0081974.t003
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Immune Analytes and DILI Outcomes
Our modeling process selected low levels of 4 immune
analytes (IL-9, IL-17, PDGF-bb and RANTES) and serum
albumin to be used for prediction. Step 1 of the modeling
process showed that 7 cytokines (TNFα, IL-12, IL-17, IL-4, IL-5,
IL-13, IL-9), 2 chemokines (MIP-1β, RANTES), 2 growth factors
(FGFb, PDGF-bb) and albumin were significantly (at level of
0.01) associated with death within 6 months of DILI onset
based on univariate analyses (Table 5). Four cytokines (TNFα,
IL-4, IL-5, IL-12) and one growth factor (FGFb) were excluded
in step 2 due to their significant correlations with the highest
ranked cytokine IL-17 and highest ranked growth factor PDGF-
bb (based on p-values). Cytokine IL-13 was excluded in step 3
because it was poorly modulated based on the heat map of
cytokine expression profile (Figure 5, Figure S1). MIP-1β was
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Low values of immune analytes and low values of serum
albumin were predictive of early death with estimated AUCs
(95% CI) of 0.79 (0.65, 0.93) for IL-9, 0.86 (0.67, 1.0) for IL-17,
0.84 (0.68, 1.0) for PDGF-bb, 0.90 (0.81-0.98) for RANTES,
and 0.83 (0.73, 0.94) for serum albumin. The AUC (95% CI) of
the linear combination of these variables based on the logistic
regression model was 0.98 (0.95, 1.0). Because the values of
the immune analytes were highly skewed, binary variables
were created to combine and to summarize the information
from these variables. The observed median values of the four
immune analytes and the known cut point of 2.8 g/dL (used in
the Child-Turcotte-Pugh scoring system for identifying subjects
with severe [class C] liver disease) for albumin were used to
dichotomize the continuous variables into binary variables.
Subjects in the DILI cohort with a baseline value of serum
albumin greater than 2.8 g/dL all survived with 100% NPV,
whereas all of those who died within 6 months of DILI onset
had values below this cutoff with 100% sensitivity (Table 6).
The binary variable based on the final four immune analytes
(IL-9, IL-17, PDGF-bb and RANTES) had estimated PPV, NPV
and accuracy of 67%, 97% and 92%, respectively, if values of
four immune analytes were all below the observed medians.
Combination of the four binary immune analytes and binary
serum albumin provided optimal differentiation between those
who died of acute DILI or survived for at least six months (and
usually recovered completely). Using this benchmark, 67 (97%
NPV) out of 69 subjects with IL-9 >13.6, IL-17 >45.2, PDGF-bb
>4207, RANTES >2529 (all pg/mL) or albumin >2.8g/dL
survived the acute DILI event at 6 months, whereas 7 (88%
PPV) out of 8 subjects with IL-9 <13.6, IL-17 <45.2, PDGF-bb
<4207, RANTES <2529 (all pg/mL) and albumin ≤2.8g/dL died
within 6 months of DILI onset (Table 6). The overall accuracy of
prediction is 74/77=96% (95% CI, 92%-100%). Baseline MELD
scores were also explored for predictability for early death. As
shown in Table 7, MELD scores [31] also were predictive ,
albeit not as accurate as the combined binary variable of 4
immune analytes and albumin.
Discussion
We performed extensive profiling of serum immune analytes
in subjects with carefully studied, prospectively followed acute
DILI, and compared results to those of normal controls. The
main findings of this work are that 1) profiles of serum immune
analytes are altered in acute DILI; 2) such profiles may be
classified into different types; 3) profiles are not specific to or
correlated with the underlying drug causes of DILI, with the
pattern of DILI, whether hepatocellular, cholestatic, or “mixed”,
nor with the R value at baseline or at later time points; and 4)
low values of serum albumin and a summary variable of only
four immune analytes at DILI onset (IL-17, IL-9, PDGF-bb and
RANTES) are predictive of who will survive and who will not
survive for 6 months after an acute DILI event. These results, if
confirmed, will advance our fundamental understanding of the
pathogenesis and progression of DILI and our ability to predict
early in the course of acute DILI those subjects who are likely
to survive or not survive.
With respect to advancing our understanding of
pathogenesis of DILI, differing immune response patterns are
suggested from analysis of cytokine profiling of DILI subjects
Table 5. Serum levels at DILI onset of immune analytes significantly associated with death within 6 months of DILI onset.
 Died [n = 10] Survived [n = 68] p value*
 Median Min. Max. Median Min. Max.  
Cytokines        
TNFα 0.5 0.0 30.9 20.1 0.0 326.5 0.001
IL-12 3.1 0.0 27.4 16.7 0.0 2185.6 <0.001
IL-17 8.6 0.0 156.7 47.4 0.0 139.1 <0.001
IL-4 2.3 0.0 5.8 5.8 0.5 12.7 <0.001
IL-5 1.1 0.0 4.9 3.0 0.0 68.4 0.006
IL-13 0.7 0.0 4.0 2.8 0.0 130.1 <0.001
IL-9 6.7 0.0 17.1 15.5 0.0 2194.2 0.003
Chemokines        
MIP-1β 55.1 19.3 133.1 92.4 15.6 473.8 0.006
RANTES 1412.8 190.0 2301.2 2740.6.8 761.4 65180 <0.001
Growth Factors        
FGFb 0.0 0.0 15.7 13.5 0.0 67.9 0.003
PDGF-bb 487.0 65.3 7313.1 4719.4 130.9 28757 <0.001
Clinical Lab        
Albumin 2.3 1.8 2.8 3.1 1.8 4.9 0.001
Analyte results are pg/mL. Values listed as zero are out of assay operating range.
* Comparisons of distributions are statistically significant (p≤0.01) by Wilcoxon rank sum test
doi: 10.1371/journal.pone.0081974.t005
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that we believe provide valuable new insights. It is increasingly
clear that DILI is often due to an exuberant immunological
response to a drug (or drug metabolite), usually bound to host
proteins. For example, serum albumin has been implicated as
a frequent carrier of drug-derived haptens [32,33]. These
complexes have been linked to immune responses that lead to
liver injury [10,34]. Such responses, directed chiefly at
hepatocytes or at bile ductular cells, may also attack other
organs and tissues, particularly the skin, the kidneys or the
bone marrow [35]. The current paradigms for immunological
characterization of DILI [e.g., as auto-immune-like or immuno-
allergic] are based on clinico-pathological manifestations of the
disease, presence of auto-antibodies (adaptive immunity),
eosinophilia (innate immunity) and/or skin rash [10,36]. Auto-
immune type DILI tends to have a delayed onset and tends to
evolve slowly on re-challenge [37]. Skin rashes, a mark of
immuno-allergic-like DILI, can be triggered by either innate
immune or adaptive immune components (e.g., DRESS
syndrome, systemic lupus erythematosus) [38,39]. Taken
together, the prototypical auto-immune-like or immuno-allergic
categories of DILI show overlap, which is in keeping with
clinical experience, with data in the US DILIN database, and
with recent clinical reports from DILIN [[40-43], Rockey et al,
Russo et al, unpublished observations]. Our cytokine profiling
analyses highlight the innate immune component in DILI (19/78
subjects), and we found a distinct adaptive immune component
at DILI onset that is mostly cellular (21/78 subjects).
Interestingly, abnormal classical or canonical TH1 and TH2
adaptive cytokine expressions were rare in the DILI cohort
investigated (4/78 subjects), whereas exuberant TH17 and TH9
adaptive immune responses were more prevalent (17/78
subjects).
This study has several strengths: we have carefully studied
78 subjects with DILI of known acute onset. We have extensive
historical and clinical data on these subjects, and we have
cytokine profiles performed with state-of-the-art methods. We
have developed a novel modeling process for data reduction
utilizing immune principles. The final single binary predictor is
relatively easy to use, requiring measurement of only serum
albumin and four immune analytes early in the course of the
Table 7. Deaths actual vs. predicted, using MELD scores at
baseline for DILI subjects (n=34).
MELD Score n Actual Deaths Predicted Deaths
>40 2 0/2 = 0% 71.3%
30-39 5 4/5 = 80% 52.6%
20-29 10 2/10 = 20% 19.6%
10-19 16 0/16 = 0% 6.0%
<10 1 0/1 = 0% 1.9%
[Unfortunately, all data necessary for the calculation of MELD scores were
available for only 34 of the 78 subjects studied, including 6 of the 10 who died
within six months. The values often missing were the serum creatinine and INR.]
doi: 10.1371/journal.pone.0081974.t007
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disease. This binary predictor seems to have high accuracy in
predicting death of acute DILI [Table 6]. Of particular
importance is that two fundamentally different strategies
employed to analyze immune analyte measurements, i.e., a
strategy based upon the known biological function and
regulation of immune analytes and a statistical/mathematical
strategy, based upon the results observed in these studies,
converged to give two main findings: 1) IL-17 (and to a lesser
extent IL-9) are key contributors to the pathology of DILI at
onset (more precisely DILI with an “adaptive immune” profile),
and 2) low IL-17/IL-9 serum concentrations are associated with
poor prognosis of DILI, or reciprocally, DILI with an “adaptive
immune” profile is associated with a good prognosis.
Our results also suggest that subjects with acute DILI who
have low levels of IL-9, IL-17, PDGF bb, RANTES, and serum
albumin are at especially high risk of dying. Thus, perhaps,
they should be treated with glucocorticoids or other immuno-
modulating drugs and should be considered early for liver
transplantation, because of their greater risk of acute death.
They also might reasonably be the focus of possible new drugs
or therapeutic approaches, such as the use of IL-10 or other
anti-inflammatory biologic agents. Nevertheless, recent studies
in patients with other forms of inflammatory liver diseases have
not shown benefit of anti-TNF agents [44-47] or IL-10 [48-50],
and the use of any of these agents would likely increase the
risk of infections. Thus, they should be used in acute DILI only
in the context of carefully designed clinical trials.
A relative weakness of the study is related to the variation of
individual cytokine measurements among subjects at DILI
onset. Establishing cytokine profiles proved heuristically useful
in that it allowed the identification of recurrent immune patterns
and helped to order a large data set, but as many as a third of
the patients did not fall into a unique, defined immune group.
Such heterogeneity is not unexpected considering the nature of
the cohort investigated (numerous causative drugs, various
underlying conditions…). Another key component of immune
profiling, namely, timing, also is worthy of comment. Each
sample represents a snapshot in time, and cytokine profiles
may be different at different time points. To minimize such
possible effects, all subjects in our cohort were enrolled within
14 days of DILI onset. Because comparisons of the profiles for
those enrolled within the first 7 days vs. those enrolled between
days 7 and 14 after onset did not reveal any significant
differences [data not shown], it is unlikely that enrolling
subjects earlier [e.g., within 7 days] will reduce variability.
Nonetheless, it would have been preferable to have had
additional time points and samples, however, the design of the
study did not include any. Thus, the heterogeneity of the
subjects studied [particularly, the large number of inciting
drugs, different genders, ages, ethnicity, etc] and the fact that,
at baseline we were able to study only a single time point, are
limitations of our study. Because of the relative rarity of acute
DILI, we nevertheless believe that our data are the most
extensive thus far obtained and analyzed carefully and, thus,
represent useful and important new knowledge.
In summary, there are characteristic profiles of cytokines in
sera of subjects with acute, clinically important DILI, and these
profiles appear to be useful for predicting who will live or will
die or require liver transplant within six months of DILI onset.
We plan to investigate whether these results will be confirmed
in larger cohorts and to compare them to the profiles that
develop in subjects with other types of acute liver injury. We
hope that other investigative groups will do so as well.
Supporting Information
Figure S1.  Profiles of immune analytes in serum at onset
of DILI. Individual cytokine concentrations in sera obtained
close to (within 14 days of) DILI onset were recorded for each
patient and compared with healthy “normal” means ± SD
values. Abnormal serum cytokine concentrations at DILI onset
were defined as values that were higher (red) or lower (blue)
than those of the means for normal controls. The profiles of
DILI subjects at onset were defined based on observed
similarities of patterns and upon knowledge of the physiologic
roles of the analytes (see text and Fig 1).
(TIF)
Figure S2.  Profiles of cytokines in sera of DILI subjects at
6-month follow-up. Individual cytokine concentrations in 6-
month follow-up sera were recorded for each patient and
compared with healthy “normal” means ± SD values. Abnormal
serum cytokine concentrations at 6-mo follow-up were defined
as measurements SD higher (red) or lower (blue) than those of
the means for normal controls. The profiles of DILI subjects at
6 month follow up were defined based on observed similarities
of patterns and upon knowledge of the physiologic roles of the
analytes (see text and Figure 1).
(TIF)
Figure S3.  Cytokine profiles in sera of subjects who died
within 6 months of DILI onset. Individual cytokine
concentrations were recorded for each patient and compared
with healthy “normal” means ± SD values. Abnormal serum
cytokine concentrations were defined as measurements SD
higher (red) or lower (blue) than those of the means for normal
controls. The profiles of DILI subjects who died within 6 months
of DILI onset were based on observed similarities of patterns
and upon knowledge of the physiologic roles of the analytes
(see text and Figure 1).
(TIF)
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